SCHEMBL1743892

SCHEMBL1743892

CCCOC(=O)[C@@H](NP(=O)(Cl)Oc1cccc2ccccc12)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HTR1B P28222 5/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
BTN3A1 O00481 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
OGG1 O15527 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
HTR1D P28221 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10208314 1.00 KMT2A (0.44) KMT2AKDM4EALDH1A1HPGDHTR1B
SCHEMBL722519 0.88 TACR3 (0.46) KMT2AKDM4EALDH1A1
SCHEMBL10208307 0.87 KMT2A (0.42) KMT2AKDM4EALDH1A1HPGDBTN3A1
SCHEMBL10208315 0.87 KMT2A (0.42) KMT2AKDM4EALDH1A1HPGDBTN3A1
SCHEMBL10208309 0.86 ALDH1A1 (0.41) KMT2AKDM4EALDH1A1HPGDTDP1
SCHEMBL10208298 0.86 ALDH1A1 (0.41) KMT2AKDM4EALDH1A1HPGDTDP1
SCHEMBL10208163 0.86 ALDH1A1 (0.40) KMT2AKDM4EALDH1A1HPGDHTR1B
SCHEMBL722413 0.84 ALDH1A1 (0.40) KMT2AKDM4EALDH1A1HPGDTDP1
SCHEMBL1274611 0.80 CNR2 (0.41) KMT2AKDM4EALDH1A1HPGDHTR1B
SCHEMBL722302 0.79 MEN1 (0.42) KMT2AKDM4EALDH1A1HPGDSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759318-B2 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections INHIBITEX, INC. (US) 2014-06-24 US disclosed
US-8759318-B2 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections INHIBITEX, INC. (US) 2014-06-24 US disclosed
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2012-03-01 US disclosed
EP-2385951-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS University College Cardiff Consultants, Ltd. (GB) 2011-11-16 EP disclosed
US-20110254856-A1 MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL LG ELECTRONICS INC. (KR) 2011-10-20 US disclosed
WO-2010081082-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) 2010-07-15 WO disclosed
WO-2010081082-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections PNP, SAMHD1, MTAP KMT2A 3637/4885KDM4E 4140/4885ALDH1A1 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.